ClinicalTrials.gg
CompletedNCT03388138Updated Mar 17, 2022Results posted

Clinical Evaluation of Etafilcon A With Ketotifen

A Phase 2 interventional study of etafilcon A with ketotifen and 1-Day ACUVUE in Visual Acuity, sponsored by Johnson & Johnson Vision Care, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-17.

Sponsored by Johnson & Johnson Vision Care, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This clinical study is a randomized, double-masked, bilateral, controlled, two-arm parallel group, multi-site, 1-Week, 2-visit dispensing study. Subjects between the ages of 18-40 will be randomized into a placebo arm or an investigational K-Lens arm.

02

Conditions studied

  • Visual Acuity
03

In context

Lead sponsor

Johnson & Johnson Vision Care, Inc. is the lead sponsor of 221 studies on the registry; 1 is open to participants now.

Of its 111 completed or terminated interventional studies of FDA-regulated products, 103 (93%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study

    1. The subject must read, understand, and sign the STATEMENT OF and receive a fully executed copy of the form.
    2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
    3. Between 18 and 39 (inclusive) years of age at the time of baseline visit.
    4. The subject must be a habitual lens wearer for a least 6 days/week and for a minimum of 8 hours per day over the last month.
    5. The subject's contact lens correction must be in the range of -1.00 D to -6.00 D (inclusive) in each eye.
    6. The subject's refractive cylinder must be 1.00 D or less in each eye.
    7. Have a spherocylindrical best corrected visual acuity of 20/30 or better in each eye (Snellen Visual Acuity).

Exclusion criteria

Exclusion Criteria:

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:

    1. Currently pregnant or lactating.
    2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious diseases (e.g., ), disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
    3. Use of systemic medications (e.g., chronic use) that are known to interfere with contact lens wear.
    4. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
    5. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear, history of strabismus, or current monovision, multi-focal, or toric contact lens correction.
    6. Any current use of rewetting drops or ocular medication.
    7. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
    8. Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA Biomicroscopy Scale.
    9. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear.
    10. Any known or allergic reaction to ketotifen.
    11. Participation in any eye drop, contact lens or lens care product clinical trial within 14 days prior to study enrollment.
    12. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
143 participants (actual)

Study arms

  • Active comparator
    K-Lens

    etafilcon A with ketotifen. Subjects between the ages of 18-40 will be randomized into the K-Lens arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.

    Combination Product: etafilcon A with ketotifen

  • Placebo comparator
    Placebo Contact Lens

    1-Day Acuvue. Subjects between the ages of 18-40 will be randomized into the Placebo arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.

    Device: 1-Day ACUVUE

Interventions

  • Combination productetafilcon A with ketotifen

    Drug page: KetotifenStudies of KetotifenKetotifen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Etafilcon A with ketotifen

  • Device1-Day ACUVUE

    1-Day ACUVUE

06

What researchers measure

Primary outcomes

  1. Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population)

    Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.

    Time frame: Baseline (Visit 1) and 1-week follow up (Visit 2)

  2. Monocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population)

    Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.

    Time frame: Baseline (Visit 1) and 1-week follow up (Visit 2)

Secondary outcomes

  1. The Number of Eyes With Clinically Significant Slit Lamp Findings

    Slit lamp findings were assessed using a biomicroscope for each subject eye at all scheduled and unscheduled visits. Clinical significant slit lamp findings are defined as Grade 3 or Grade 4. (Grade 0=None, Grade 1=Trace, Grade 2=Mild, Grade 3=Moderate and Grade 4= Severe). The data was dichotomized as 1=Grade 3 or Grade 4 and 0, otherwise. The number of eyes with clinically significant slit lamp findings for each lens type was reported.

    Time frame: Up to 1-Week Follow-up

  2. The Number of Eyes With Unacceptable Lens Fitting

    Lens fit was assessed for each subject and eye using a biomicroscope. Unacceptable lens fit was assessed at all scheduled and unscheduled visits. A subject was deemed to have an unacceptable lens fitting if they met any of the following criteria: (1) Limbal exposure at primary gaze with extreme eye movement, (2) edge lift, (3) excessive movement in primary up gaze, (4) insufficient movement in all three of the following conditions: primary gaze, up gaze and push up test. The number of eyes with unacceptable lens fitting was reported for each lens type.

    Time frame: Up to 1-Week Follow-up

07

Results

Posted Mar 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneEtafilcon A With KetotifenEtafilcon A
Started9447
Completed9347
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryMonocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population)

Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.

Time frame:
Baseline (Visit 1) and 1-week follow up (Visit 2)
Reported as:
Mean · logMAR
Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population)
logMAREtafilcon A With KetotifenEtafilcon A
Visit 1 (Baseline)-0.111 ± 0.0702-0.109 ± 0.0809
Visit 2 (1-week follow up)-0.115 ± 0.0717-0.118 ± 0.0814
Statistical analysis
  • Etafilcon A With Ketotifen vs Etafilcon A · Linear Mixed Model · Least-square mean difference: 0.0017 · 95% CI -0.021 to 0.025LS Mean difference was calculated as etafilcon A with ketotifen - etafilcon A
PrimaryMonocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population)

Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.

Time frame:
Baseline (Visit 1) and 1-week follow up (Visit 2)
Reported as:
Mean · logMAR
Monocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population)
logMAREtafilcon A With KetotifenEtafilcon A
Visit 1 (Baseline)-0.109 ± 0.0740-0.110 ± 0.0806
Visit 2 (1-week follow up)-0.115 ± 0.0717-0.117 ± 0.0815
Statistical analysis
  • Etafilcon A With Ketotifen vs Etafilcon A · Linear Mixed Model · Least-square mean difference: 0.0007 · 95% CI -0.022 to 0.024LS Mean difference was calculated as etafilcon A with ketotifen - etafilcon A
SecondaryThe Number of Eyes With Clinically Significant Slit Lamp Findings

Slit lamp findings were assessed using a biomicroscope for each subject eye at all scheduled and unscheduled visits. Clinical significant slit lamp findings are defined as Grade 3 or Grade 4. (Grade 0=None, Grade 1=Trace, Grade 2=Mild, Grade 3=Moderate and Grade 4= Severe). The data was dichotomized as 1=Grade 3 or Grade 4 and 0, otherwise. The number of eyes with clinically significant slit lamp findings for each lens type was reported.

Time frame:
Up to 1-Week Follow-up
Reported as:
Number · Number of Eyes
The Number of Eyes With Clinically Significant Slit Lamp Findings
Number of EyesEtafilcon A With KetotifenEtafilcon A
The Number of Eyes With Clinically Significant Slit Lamp Findings00
SecondaryThe Number of Eyes With Unacceptable Lens Fitting

Lens fit was assessed for each subject and eye using a biomicroscope. Unacceptable lens fit was assessed at all scheduled and unscheduled visits. A subject was deemed to have an unacceptable lens fitting if they met any of the following criteria: (1) Limbal exposure at primary gaze with extreme eye movement, (2) edge lift, (3) excessive movement in primary up gaze, (4) insufficient movement in all three of the following conditions: primary gaze, up gaze and push up test. The number of eyes with unacceptable lens fitting was reported for each lens type.

Time frame:
Up to 1-Week Follow-up
Reported as:
Number · eyes
The Number of Eyes With Unacceptable Lens Fitting
eyesEtafilcon A With KetotifenEtafilcon A
The Number of Eyes With Unacceptable Lens Fitting01

Adverse events

Collected over Throughout the entire duration of the study. Approximately 1-Week per subject.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etafilcon A With Ketotifen0/94 (0%)0/94 (0%)0/94 (0%)
Etafilcon A0/47 (0%)0/47 (0%)0/47 (0%)

Baseline characteristics

All subjects that were dispensed a study lens.

Age, Continuous
Age, Continuous(years)Etafilcon A With KetotifenEtafilcon ATotal
Mean30.4 ± 4.9829.6 ± 4.5630.1 ± 4.84
Sex: Female, Male
Sex: Female, Male(Participants)Etafilcon A With KetotifenEtafilcon ATotal
Female593190
Male351651
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Etafilcon A With KetotifenEtafilcon ATotal
Asian415
Black or African American7310
White8343126
Region of Enrollment
Region of Enrollment(participants)Etafilcon A With KetotifenEtafilcon ATotal
United States9447141
08

Study locations

6 sites
  • Vue Optical Boutique
    Jacksonville, Florida 32205, United States
  • Maitland Vision Center
    Maitland, Florida 32751, United States
  • St. Lucy's Vision Center
    Tampa, Florida 33625, United States
  • Kannarr Eye Care
    Pittsburg, Kansas 66762, United States
  • Sacco Eye Group
    Vestal, New York 13850, United States
  • Botetourt Eyecare, LLC
    Salem, Virginia 24153, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Feb 2018, 2 months.

Results were first posted in Mar 2021, 3 years 1 month after primary completion. A results delay was requested in Feb 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2017
First posted
Jan 2, 2018
StartActual
Dec 6, 2017
Primary completionActual
Feb 9, 2018
CompletionActual
Feb 9, 2018
Results delay requested
Feb 4, 2019
Results first posted
Mar 16, 2021
Last update
Mar 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03388138
Responsible party
Sponsor
First posted
Jan 2, 2018
Start date
Dec 6, 2017
Primary completion
Feb 9, 2018
Completion
Feb 9, 2018
Results posted
Mar 16, 2021
Last update
Mar 17, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketotifen

Start the discussion